The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...
A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...
Measuring treatment success in Sjögren's disease requires more than tracking systemic disease activity alone. Fatigue, pain, ...
When patients provide information about how they are doing, including symptoms, functionality, and quality of life, scientists can use this data, called patient-reported outcomes (PROs), to conduct ...
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II ...
Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback